Lenalidomid Pharmascience

Lenalidomide, the active ingredient in Lenalidomid Pharmascience, is an immunomodulatory drug presented as a tablet for oral use. It treats multiple myeloma and myelodysplastic syndromes in adult patients.

GNH USA supplies Lenalidomid Pharmascience as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Lenalidomide is employed in hematologic malignancies and related bone‑marrow disorders.

Multiple myeloma: improves disease control and prolongs survival in relapsed or refractory patients. Myelodysplastic syndromes with del(5q): reduces transfusion dependence and improves blood counts. Mantle cell lymphoma (in approved regions): contributes to response rates when used in combination regimens.

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Neutropenia: reduced neutrophil count increasing infection risk. - Thrombocytopenia: lowered platelet levels that may cause bleeding. - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may lead to dehydration. - Rash: mild skin eruptions. - Constipation: difficulty passing stools.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Secondary primary malignancies: emergence of new cancers. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic failure: significant liver enzyme elevation and dysfunction. - Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances. - Interstitial lung disease: inflammation of lung tissue leading to breathing difficulties.

When prescribing Lenalidomid Pharmascience, clinicians should observe several precautionary measures.

Monitor blood counts: perform regular CBC to detect neutropenia or thrombocytopenia. Assess thrombotic risk: evaluate need for prophylactic anticoagulation. Avoid use in pregnancy: drug is contraindicated due to teratogenicity. Adjust for renal impairment: dose may need modification in reduced kidney function. Counsel on contraception: effective birth control required during and after treatment. Store at room temperature: keep in original packaging, protect from moisture and light.

Lenalidomid Pharmascience can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly lower lenalidomide exposure. - Anticoagulants (e.g., warfarin): increased risk of bleeding when combined. - Live vaccines: heightened risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may raise plasma levels modestly. - NSAIDs (e.g., ibuprofen): can exacerbate thrombocytopenia. - Hormonal contraceptives: possible reduced effectiveness. - Other myelosuppressive agents: additive bone‑marrow toxicity. - Digoxin: slight increase in serum concentration.